interpreting the term,brief,pay the sum,independent source,copy of the terms,claim,reference to the salient features,reasonable,pharmaceutical,only reliable method,d,erroneous basis,certain special right,promoter,concern,ends,counter to the principles,is the only reliable method,per,legal issue,account by the valuer,reserves,dil,original research products,point,that basi,date,nature,ex - parte injunction,other hand,listed company,today,indian,following order,application,tax,price of market transactions,solvay pharmaceuticals bv,reason,intrinsic worth of the company dil,public limited company,rs,discrepancies,indicative,question of valuation,enclosure,letter,reason for non - inclusion,the party,taking the dividends,above decision,instant,independent  third party  projection,asset and earnings based value,company  business,sum,combined,sb billimoria,important,profit - earning capacity,exchange,important aspect,appropriate,interpreting the terms,moreover,words,vast discrepancies,three methods,reasons,matter,circumstances,four weeks,prejudice,mrs,carries no special right,existing assets,only a small proportion,carries special right,increase,stipulated date,tables,next objection,discrepancy,forms,two suit,agreement,extant,petitioner - plaintiff applied,share value,fulfillment,nature of the dispute,dealings,consideration,appeals in this court,error,point of time,share in a public,therein the value,dupen laboratories private ltd,persuasive impact,stipulation,vasant,provision,two company,stipulated date of submission,amount of profits,incorporation,relevant data,said  share,is the last word,thwart the terms,value  asset,indian promoters,ltd,relevant material,fide nature,projections,declaration,months,are vast discrepancies,defendants,city,petitioners during this period,result ias,aggrieved parties,benefit,express term,assessing the intrinsic worth,give any direction,two method,decision,given fact,cpc,is the value,other word,companies,supplementary valuation report,volume,of the intrinsic value,adding control premium,defendant companies,addition,where the shares,decisions in dean v prince,be the value,contemplate the valuation,shareholders,busines in vertin,other suits,obligation,special or distinctive characteristic,analysi,recommended value,colopsa,vast discrepancies between the projection,submit a supplementary valuation report,relevant date,decision in dean v prince,subject matter,vacating the ex-parte injunction,foreign,buyer  seller of the share,errors,definite increase in the share value,other two appeals,gift tax,kumar,private limited company,legal,slp,instant case,such method of valuation,p venkatarama reddi,applying the percentage,ym,true,research product of the foreign promoter,duphar,demonstrably wrong approach,thereto a control premium,capitalization,extraneou,three appeal,that the market,indicated the implication,element of control premium,apparent,ia no,relevant record,writing,colospa,evaluation,money,wrong,dupen,pharmaceutical companies,discounted,company dil,para,flow,value on the basis,that consideration,has a persuasive impact,trial judge,reliable figure,final order in terms,non addition of control premium,necessary,respective,statutory,aspect,foremost,relevant datum from independent sources,reflecting the profit-earning capacity,future earning,original,memorandum,parties state,only  per cent shares,of the share capital,special weightage in the form,mumbai,shri d,companies act before the central government,withdraw various suit,high court,source,accountant,th,phase  perception,advice,one direction,approach,solvay pharmaceuticals,non-inclusion,plaintiffs,issue as regards,four week,other two suits,cent for a period,given relevant reasons,asset value,where the share,ages,plaintiff,find no merit,other brands,objections,manu,commissioner of gift tax,issue,suit osno,mr,principle,dupen laboratory,phase  perception of the market andor industry,assets of dil,intrinsic,characteristics,not the case,reasonable commercial basi,sb,order of the high court,fide nature of the dispute,aggrieved defendant,appropriate weight ages,carries no special rights,dealing,month,dpil,shri vasant kumar,discrepancy between the projection,legality,cash flow method,decisions to the extant,weeks from today subject,state,certain,share,time,brands,capable,last word,st,express,special advantage to the holder,combined shareholding of the promoters,colopsa brands,cent shares of the petitioners,counsel,account of these shares,jalan,shares,third party  projections,sc,disposed,give effect,contentions,mode,point in time,net free cash flow of a business,laboratories private limited,representing the value,andor the company,intrinsic worth,is part,third party,filing ia no,week,objection,characteristic,product,two brands,relevant reason for non-inclusion,plea,vast,root of the valuation,solvay,future earnings,enclosures,research,market price,necessary implication,valuation,basi,controversial,extraneous issue as regard,used methodology for future earnings,regarding valuation,salient,defendants - respondent,relevant data from independent sources,past,expres,asset of dil,brief reference to the salient features,last word on the subject,incidental matters,total consideration,parte,bombay v smt,share capital,cases,treating,case of the petitioners,also the appeal,submissions,method,civil,interfran,vijay,capitalization of past earnings,injunction,business,view,contentiou,original research product of the foreign promoter,approval,solvay pharmaceutical bv,yh,indicated the implications,direction in regard,patent mistake,payment for shares,value of the shares,mahadeo jalan,petitioner - plaintiff applied for an interim injunction,date for valuation,trademark,right,future maintainable profit,or distinctive characteristics,products,renuka datla,excluding those brands,valuation of shri malegam,circumstance of the case,value of a company  business,brands vertin,bullish phase  perception of the market andor industry,salient features,other modes of valuation,above direction,two companies,decisions,certain special rights,other modes,integral,control,have some additional value,having regard,rule,possible that the market,terms of the settlement,datum from independent sources,above value,central government,withdraw the suit,capitalizing the past earning,forms part,intrinsic value of the share,decision to the extant,laboratories,petitioner,combined holding,capacity of the company,respective contentions,validity of the transfer,retained the money,solvay pharma india ltd,aggrieved party,asset based value,capital,profit,basis,amount,result,weightage,pvt,period,restraining the defendants-respondent,rights,erroneou,certain principle,covering letter,breach,are vast discrepancy,special right,perceptions,m,kusumben d mahadevia manuscmanusc,percentage,therein,p,due regard,patent,advantage,bombay,clear that the above value,issue as regard,due regard to the terms,nos,parties to the settlement,shall effect,notwithstanding the finality,possible,subject to the above direction,method of evaluation,liable,court master,basi of a holding,has no investment,party,submission,hyderabad,commonly used methodology,mumbai-,total,pharmaceutical company,s,interfran ltd,third,market based value,existing asset,main,end of justice,march,two week,contentions in this regard,present slps,fact that the respondents,shri,percentage to the intrinsic worth,is the contention,three method,rise,large amount of profits,are the wife,license,form,advantage to the holder,standard method of valuation,copy,duphar pharma india ltd,applying the standard,given point,transfer of shareholdings,court,restraining the defendants-respondents,having due regard,respective contentions in this regard,capacity,datla under section,therefore,adding the element,relevant reasons,interim,indicative of a bullish phase  perception of the market andor industry,orders,merit,act,following weight ages,only reliable method of  earnings,argument,facts,aggrieved defendants,commercial basis,bona,buying the other share,certain principles,variou,dividend method,last,express terms,standard,learned senior counsel,persuasive,small proportion of the profits,case manuscmanusc,order in terms,incidental,reserve,fundamental error,impact,commonly accepted method,stock exchange,appropriate weight age,petitioner in the first slp,value of the  vertin,obtaining expert legal advice,fundamentally erroneous basis,pa,colospa  brand,july,excluding those brand,burges,third respondent,appropriate angle,determining the intrinsic worth,contractual obligations,obligations,extraneous issue,wrong approach,son,hearing the slps,vasant kumar,practical reality,contemplate valuation,pay the interest,pending disposal,market perceptions,earnings,costs,large,colospa brands,companies act,first and foremost contention,implication,ad,erroneous,defendants - respondents,indian promoter,venkatarama,benefit of higher valuation,used methodology,bullish,chartered accountant,opportunity,terms of mutual settlement,malegam,marked,only  per cent share,value,particular,part of the intrinsic value,suit of similar nature,market transactions,said share,said decisions,valuation in addition,vast discrepancy,higher valuation,free cash flow of a business,standard methods of valuation,orders in terms,infringe the principles,burgess,asset,applying the standard methods,be the profit-earning method,forms part of the combined holding,commercial basi,salient feature,specific and clear terms,discrepancies between the projection,shri ym,mr vasant kumar,holder,learned valuer,implementation,dcf method,seller,infringe the principle,reference to the profits,- inclusion,ex,petitioners,other formality,various suit,higher,evaluate the intrinsic worth,various,profit earning method,regards,fact,are the original research product,past performance,common,secured the relevant data,had the benefit,petitioner in slpnos,additional,limited,matters,cent shareholding by the petitioners,word,other share,non - inclusion,non addition,distinctive characteristic,methods,business in vertin,modes of valuation,cash,brand of drugs,civil court,two pharmaceutical companies,average maintainable profit,shares in dil,concerning the interest,contractual obligation,profit - earning method,features,account,first,indian promoters  shareholding,opportunity to the respective parties,billimoria,share in dil,privilege,sons,said two companies,per cent shares,company  busines,assets,reality,discount,adding the control premium,adopting this method,control premium,ias,worth,main objections,prayer,trial,canos,wherein,fundamental,based value,proper method,main objection,finality,specific,irrelevant material,free,receipt of share transfer forms,weightage in the form,formality,applicable,weight ages,respondent,relevant reasons for non-inclusion,accepting this principle,average maintainable profits,clear term,chartered,first slp,maintainable profits,settled the dispute,osno,two pharmaceutical company,case,projection,special or distinctive characteristics,commissioner,extraneous,are dealings,purchase,grant of interest,capitalizing the past earnings,laboratories private ltd,due,sum of rs,respondent shri vasant kumar,given this direction,dividend,applying the standard method,thwart the term,table,earning based valuation,government,payable to the petitioners during this period,contentious,clear from this decision,price,buyer,merit in this argument,appeal,rules,of the intrinsic worth,view that the valuer,party to the settlement,shareholder,modes,disputes,of  and interim injunction,value of vertin,to the petitioners during this period,contention,private ltd,shares in a public,not the existing asset,contentious issue,decision of the valuer,that the above value,term of the settlement,placed any fact,given facts,parties,relevant datum,basic principle,non - inclusion of vertin,definite increase,other objection,mind,sources,runs counter,dr vijay kumar datla,accepted method,part,validity,--the,value of the share,slpno,expert legal advice,disposal of the suit,kusumben,past earning,other mode,appropriate discount rate,terms,are the original research products,special weightage,following weight age,transaction,performance,irrelevant,impleading the company,j,formalities,cent shares,transfer of shares,payable,value with appropriate weight ages,affect the valuation,vast discrepancy between the projection,such stipulation,hand,dcf method of valuation,basis of a holding,impleading the companies,figures,an important aspect,represent the value,said two company,treatment,senior,valuation of the shares,petitioner in slpno,proper method of valuation,ends of justice,claims,covering,relevant records,form of reserves,final orders,dividends,future,dean,angles,property of dil,rate,reference,worth of the shares,proper,discounted cash flow method,erroneous basi,taking the dividend,reddi,appeal in the high court,proportion of the profits,method of valuation,uppermost,matter of the suits,mahadeo,final orders in terms,average,approached the question,interest,mistake,payment of interest,months within a period,cent share,future maintainable profits,shareholdings in defendant companies,relevant reason,direction,above decisions,share transfer form,common order of the high court,premium,bv,proportion,claim of the petitioners,burgess v purchase,form part,that such method,laboratories pvt,high,shareholding in defendant companies,going concerns,husband,calculation,refusal of injunction,supplementary,higher of the intrinsic value,shareholdings,intrinsic value,records,c,colopsa brand,first principle,contractual,dividend method of valuation,given rise,two suits,context,r,fide,contested the valuation,valuation report,research product,root,receipt,other party,way of dividends,pharmaceuticals,standard methods,section,buyer  seller,respondents,crores,sense,learned trial judge,not a matter,purchaser,that basis,public,rise to these slps,common order,learned senior counsel for the respondents,final order,cost,intrinsic worth of the shares,decision of this court,effect,week from today subject,mrs renuka datla,legal advice,d mahadevia manuscmanusc,share transfer forms,other formalities,other brand,overall market,higher than the value,passed the following order,specific and clear term,absence of reliable figures,scmanu,master,drugs,settled the disputes,passing the final orders,framing the terms,purchaser since the respondents,order,inclusion,unable,appeal in this court,transfer,discount rate,valuation date,crore,datla,approvals,valuer,principles,india,subject,circumstances of the case,counter,profit - earning capacity of the company,earning,implications,vertin and colopsa brands,of the indian promoters,legality of transfer,colospa  brands,said brand,prince,dupen laboratories private limited,mutual settlement,further particulars,market perception,stock,disposal,absence,third respondent by name shri d vasant kumar,special treatment,going concern,determining the intrinsic value  asset,angle,wanted a special treatment,also the appeals,two appeal,past earnings,bullish phase  perception,methodology,said  shares,two brand,combined shareholding,independent  third party  projections,adopting future,best possible method of evaluation,fact that the respondent,cent shares as part,justice,overall view,intrinsic value  asset,petitioner by the earnings,fulfillment of other formalities,investment in dupen laboratories,relevant date for valuation,suits of similar nature,reflect the profit-earning capacity,further particular,word on the subject,increase in the share value,such a provision,two appeals,discounting the net free cash flow,secured the relevant datum,respective contention,shri malegam,matter against the respondent,being the transfer,reasonable commercial basis,forming part,be the proprietor,next,settlement,commercial,name shri d vasant kumar,city civil court,claims of the petitioners,shri ym malegam,contention of the petitioners,not the asset,proprietor,regard to the terms,slpnos,filing ia nos,proceedings,petitioner during this period,element,terms of settlement,breach of contractual obligations,petitioners by the earnings,withdraw the suits,definite,wife,laboratory,counsel for the parties state,basic,jalan s case manuscmanusc,respective party,perception,distinctive,controversial legal issue,refusal,mode of valuation,limited company,foreign promoter,mr malegam,mahadeo jalans case,such an important aspect,value of shares,slpc,small,shareholding,vertin and colopsa brand,reliable figures,part of the promoters,gift,ms,petitioner - plaintiff,question,clear,relevant,marked based value,dcf,buying the other shares,figure,similar,mahadevia,not the existing assets,way,respondent by name shri d vasant kumar,cent share of the petitioners,given relevant reason,maintainable profit,concerns,slps,promoters,private,earning capacity,integral part,aggrieved,valuation of the intrinsic worth,regard,market transaction,colospa brand,busines,other shares,supply,overall,promoters  shareholding,final analysis,weight,petitioner from the market,incidental matter,be the intrinsic value,statutory approval,v,cent shareholding,worth of the company dil,to the petitioner during this period,valuation of shares,free cash flow,copy of the order,present slp,other mode of valuation,large amount,judge,subject matter of the suits,than the value,higher than the intrinsic value,above decision in the context,petitioners from the market,appropriate angles,withdrawn,interest at the rate,market andor industry,such method,addition of control premium,distinctive characteristics,- inclusion of vertin,inviting the valuer,independent,market,carries special rights,holding,original research product,are dealing,dispute,other words,said shares,term,methods of valuation,taking an overall view,placed any facts,three appeals,mutual,whatever,adopting the dcf method,valuing the intrinsic worth,privileges,final analysi,senior counsel,record,valuer s mode,earnings value,pharmaceutical bv,defendant company,brand,implementation of settlement,independent sources,profits,grant,higher weightage,ia nos,respective contention in this regard,be the property,delayed the implementation,be the claims,weight age,india ltd,age,pharma,analysis,bona fide nature,chosen the best possible method,similar nature,dean v prince,respective parties,generally accepted method,value of the brands vertin,special rights,ors,provided projections,and clear terms,present,reliable,demand,based valuation,other suit,valuation on that basis,competent,said decision,not the assets,dupen laboratories pvt,standard method,foremost contention,per cent share,extraneous issue as regards,reasons for non - inclusion,such transfer,solvay pharmaceutical,suit,interim injunction,floating stock,special advantage,and clear term,term of settlement,part of this order,smt,pharma india ltd,also an element,end,result ia,circumstance,feature,payment,find no apparent error,apparent error,other two suit,practical,net,said,fundamentally erroneous basi,or distinctive characteristic,non,consideration by the valuer,plea that the valuation,appeals in the high court,statutory approvals,week of the submission,brief reference,ad interim injunction,st march,datum,central,other two appeal,additional value,appeals,dupen laboratories,answering this question,cent,regard to the bona,drug,best possible method,ia,pharmaceuticals bv,particulars,fundamental errors,defendant,thereto,transactions,expert,force,name,weeks of the submission,data from independent sources,provided projection,various suits,of a bullish phase  perception of the market andor industry,above decisions in the context,cano,dr,give any special advantage,listed company--its market price based value,report,be the claim,vertin,investment,material,receipt of the total consideration,indicates the value,net free cash flow,co,company,than the intrinsic value,shri yh,contention in this regard,valuation in the instant case,trademark license agreement,renuka,suits,all the party,phase,er,integral part of the intrinsic value,weeks,pay interest,a provision,property,respondent shri,research products,third party  projection,effect to the settlement,independent projections,research products of the foreign promoter,final,give opportunity,all the parties,special,matter against the respondents,from this decision,language,memorandum of settlement,data,framing the term,withdraw various suits,independent projection,the parties,passing the final order,two weeks,two methods,clear terms,maintainable,small proportion,initiative,original research products of the foreign promoter,term of mutual settlement,industry,today subject